Q1 results, resolving litigation, but faces trade and NIH policy challenges. Click for my look at TXG stock prospects.

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated ...

10x Genomics is a life science technology company with a clear mission and visionary leadership. 10x Genomics delivered a solid Q3 quarter with revenue reaching $154M, growing 17% YoY. The company ...

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & services industry, including 10x Genomics (NASDAQ:TXG) and its peers.

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at where 10x Genomics, Inc. (NASDAQ:TXG) stands against the other genomics ...

10x Genomics, Inc. (NASDAQ:TXG) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. 10x Genomics, Inc., a life science technology ...

10x Genomics (NASDAQ: TXG) is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million. On the other hand, the company’s full-year revenue guidance of $620 ...

10x Genomics Inc has a consensus price target of $23.15 based on the ratings of 20 analysts. The high is $60 issued by Goldman Sachs on July 14, 2022.The low is $6.5 issued by Goldman Sachs on May ...

Genomics startup Parse Biosciences lost its bid to dismiss a patent-infringement lawsuit brought by rival 10x Genomics and Stanford University on Thursday, when a Delaware federal court denied ...

10x Genomics and Beckman Coulter Life Sciences, announce the commercial availability of a new solution to automate single cell gene expression workflows. Skip to content. Menu.

10x Genomics (NASDAQ: TXG), a biotechnology company that designs and manufactures gene sequencing technology, was listed following its IPO in September. While the stock saw some volatility post ...